Loading...
Market
What will be the market share of Efsitora in the insulin market within a year of its launch?
4
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market research reports, company financial disclosures
Story
Eli Lilly's Weekly Insulin Efsitora Effective in Type 2 Diabetes Trials
May 16, 2024, 12:29 PM
Eli Lilly announced on Thursday that its once-weekly insulin injection, efsitora, met the main goals in two late-stage trials evaluating its effectiveness in people with type 2 diabetes. The experimental insulin demonstrated blood sugar reduction consistent with commonly used daily basal insulin products. These results suggest that efsitora could offer a significant lifestyle improvement for patients by reducing the frequency of injections from daily to weekly.
View original story
Similar markets
Achieve more than 15% market share • 25%
Achieve 10-15% market share • 25%
Achieve 5-10% market share • 25%
Achieve less than 5% market share • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
<20% • 25%
20%-40% • 25%
40%-60% • 25%
>60% • 25%
Less than $1 billion • 33%
$1-2 billion • 33%
More than $2 billion • 33%
Less than 30% • 25%
30% to 50% • 25%
51% to 70% • 25%
More than 70% • 25%
Less than 5% • 33%
5% to 15% • 33%
More than 15% • 34%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Eylea retains majority market share • 50%
Biosimilars gain majority market share • 50%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Biocon's biosimilar dominates • 33%
Biogen's biosimilar dominates • 33%
Equal market share between Biocon and Biogen • 34%